The global diagnostics industry is undergoing tremendous changes in recent years.

Molecular diagnostics are rapidly transforming drug development and patient selection. Clinical trials with biomarkers have higher success rates than those without. Combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers. New molecular diagnostics can simplify decision-making and reduce uncertainty. However, they can also complicate treatment selection since multiple tests may be needed to identify markers, and their results are likely to vary in specificity and sensitivity.